A Highly Potent Non-Nucleoside Adenosine Deaminase Inhibitor: Efficient Drug Discovery by Intentional Lead Hybridization

Journal of the American Chemical Society

Volumn 126, Issue 1, 2004, Pages 34-35

  Terasaka, Tadashi ^a   Kinoshita, Takayoshi ^a   Kuno, Masako ^a   Nakanishi, Isao ^a,b  

^a ASTELLAS PHARMA INC   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; LEAD; NON NUCLEOSIDE ADENOSINE DEAMINASE INHIBITOR; NUCLEOSIDE DERIVATIVE; PENTOSTATIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYBRIDIZATION; STRUCTURE ANALYSIS; TOXICITY;

EID: 0347129832     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja038606l     Document Type: Article

References (20)

1. Thompson, L. F.; Seegmiller, J. E. Adv. Enzymol. 1980, 51, 167-210.
2. Valenzuela, A.; Blanco, J.; Callebaut, C.; Jacotot, E.; Lluis, C.; Hovanessian, A. G.; Franco, R. J. Immunol. 1997, 158, 3721-3729.
3. (a) Smith, J. F.; Poplack, D. G.; Holiman, B. J.; Leventhal, B. G.; Yarbro, G. J. Clin. Invest. 1978, 62, 710-712.
4. (b) Simpkins, H.; Stanton, A.; Davis, B. H. Cancer Res. 1981, 41, 3107-3110.
5. (a) Nakamachi, Y.; Koshiba, M., Nakazawa, T.; Hatachi, S.; Saura, R.; Kurosaka, M.; Kusaka, H.; Kumagai, S. Arthritis Rheum. 2003, 48, 668-674.
6. (b) Yuksel, H.; Akoglu, T. F. Ann. Rheum. Dis. 1988, 47, 492-495.
7. (a) Cronstein, B. N. J. Appl. Physiol. 1994, 76, 5-13.
8. (b) Ohta, A.; Sitkovsky, M. Nature 2001, 414, 916-920.
9. Franco, R.; Valenzuela, A.; Lluis, C.; Blanco, J. Immunol. Rev. 1998, 161, 27-42.
10. Bessodes, M.; Bastian, G.; Abushanab, E.; Panzica, R. P.; Berman, S. F.; Marcaccio, E. J.; Chen, S. F.; Stoeckler, J. D.; Parks, R. J. Biochem. Pharmacol. 1982, 31, 879-882.
11. Agerwal, R. P.; Spector, T.; Parks, R. E. Biochem. Pharmacol, 1977, 26, 359-367.
12. (a) McConnell, W. R.; El-Dareer, S. M.; Hill, D. L. Drug Metab. Dispos. 1980, 8, 5-7.
13. (b) Lambe, C. U.; Nelson, D. J. Biochem. Pharmacol. 1982, 31, 535-539.
14. Agarwal, R. P. Cancer. Res. 1979, 39, 1425-1427.
15. (a) Mitsuya, H.; Weinhold, K. J.; Furman P. A.; Clair, M. H. S.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
16. (b) Klecker, R. W.; Collins, J. M.; Yarchoan, R.; Thomas, R.; Jenkins, J. F.; Broder, S.; Myers, C. E. Clin. Pharmacol. Ther. 1987, 41, 407-412.
17. (a) Connolly, K. J.; Allan, J. D.; Fitch, H.; Jacksonpope, L.; Mclaren, C.; Canetta, R.; Groopman, J. E. Am. J. Med. 1991, 91, 471-478.
18. (b) Hartman, N. R.; Yarchoan, R.; Pluda, J. M.; Thomas, R. V.; Wyvill, K. M.; Flora, K. P.; Broder, S.; Johns, D. G. Clin. Pharmacol. Ther. 1991, 50, 278-285.
19. Terasaka, T.; Nakanishi, I.; Nakamura, K.; Eikyu, Y.; Kinoshita, T.; Nishio, N.; Sato, A.; Kuno, M.; Seki, N.; Sakane, K. Bioorg. Med. Chem. Lett. 2003, 13, 1115-1118.
20. The coordinates of the four complexes have been deposited with the Protein Data Bank: 2/ADA; 1NDV, 1/ADA; 1NDW, 3/ADA; 1NDY and 4/ADA; 1NDZ.